Funding Supports Clinical Development of Aria CV’s Pulmonary Hypertension System

February 25, 2020—Aria CV, Inc., a company focused on the treatment of pulmonary arterial hypertension (PAH), announced that it has completed a $31 million Series B round of financing to fund its first clinical study in the United States.

According to the company, the funding will support an early feasibility investigational study designed to evaluate long-term implantation of the Aria CV pulmonary hypertension (PH) system in PAH patients. The Aria CV PH system is an implant designed to restore the benefits of a healthy, elastic pulmonary artery, which reduces cardiac workflow and enhances blood flow, according to the company. This technology has the potential to improve both duration and quality of life as well as health care economics, states the company.

On February 6, the company announced that the Aria CV PH system received Breakthrough Device designation from the FDA.

Additionally, Aria CV has performed a successful acute first-in-human clinical study in Vienna, Austria and is now preparing for a United States clinical trial under the FDA’s Early Feasibility Study program to evaluate long-term implantation in PAH patients.

The financing was led by Xeraya Capital, a private equity and venture investor in life sciences that focuses on medical technologies, health care biotechnology, and biorenewables. Also participating in the financing were Longview Ventures, Catalyst Health Ventures, BioStar Ventures, Cedar Point Capital, Frontcourt Group, and three strategic investors, advised Aria CV.